Life Sciences»Pharmaceuticals»Therapeutic Area»CNS/Neurology
Anxiety Disorders - Pipeline Review, H2 2016
| Lowest Prices Guaranteed | Length | Publisher | Published Date | SKU |
|---|---|---|---|---|
| from $2,000 | 273 Pages | Global Markets Direct | August, 2016 | GMD15165535 |
| Lowest Prices Guaranteed | |
| Price | from $2,000 |
|---|---|
| Length | 273 Pages |
| Publisher | Global Markets Direct |
| Published Date | August, 2016 |
| SKU | GMD15165535 |
Table of Contents
Anxiety Disorders - Pipeline Review, H2 2016 Table of Contents
Global Markets Direct
- Introduction
- Global Markets Direct Report Coverage
- Anxiety Disorders Overview
- Therapeutics Development
- Pipeline Products for Anxiety Disorders - Overview
- Pipeline Products for Anxiety Disorders - Comparative Analysis
- Anxiety Disorders - Therapeutics under Development by Companies
- Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes
- Anxiety Disorders - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Anxiety Disorders - Products under Development by Companies
- Anxiety Disorders - Products under Investigation by Universities/Institutes
- Anxiety Disorders - Companies Involved in Therapeutics Development
- AbbVie Inc
- Ache Laboratorios Farmaceuticos S/A
- Adamed Sp. z o.o.
- Addex Therapeutics Ltd
- Amorsa Therapeutics Inc.
- Avineuro Pharmaceuticals, Inc.
- Azevan Pharmaceuticals, Inc.
- Biohaven Pharmaceutical Holding Company Limited
- Bionomics Limited
- Boehringer Ingelheim GmbH
- C4X Discovery Holdings PLC
- Catalyst Pharmaceuticals, Inc.
- Corcept Therapeutics Incorporated
- Edgemont Pharmaceuticals, LLC
- Eisai Co., Ltd.
- Eli Lilly and Company
- Fabre-Kramer Pharmaceuticals, Inc.
- Gabather AB
- GlaxoSmithKline Plc
- GW Pharmaceuticals Plc
- Humanetics Corporation
- IntelGenx Corp.
- Intra-Cellular Therapies, Inc.
- INVENT Pharmaceuticals, Inc.
- Lead Discovery Center GmbH
- Marinus Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KgaA
- Neuralstem, Inc.
- Neurelis, Inc.
- NeuroNascent, Inc.
- Newron Pharmaceuticals S.p.A.
- Nippon Chemiphar Co., Ltd.
- Omeros Corporation
- Otsuka Holdings Co., Ltd.
- Pherin Pharmaceuticals, Inc.
- Pragma Therapeutics
- Protagenic Therapeutics Inc.
- Suda Ltd
- Sumitomo Dainippon Pharma Co., Ltd.
- Synchroneuron Inc.
- Tonix Pharmaceuticals Holding Corp.
- Toray Industries, Inc.
- Trevena, Inc.
- TRImaran Pharma, Inc.
- Turing Pharmaceuticals AG
- Anxiety Disorders - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- 18-MC - Drug Profile
- acamprosate calcium SR - Drug Profile
- ACH-36 - Drug Profile
- ADN-2013 - Drug Profile
- ADX-71441 - Drug Profile
- ADX-71743 - Drug Profile
- ADX-88178 - Drug Profile
- alprazolam - Drug Profile
- AM-3506 - Drug Profile
- AVN-0189 - Drug Profile
- AVN-101 - Drug Profile
- AVN-628 - Drug Profile
- BNC-210 - Drug Profile
- brexpiprazole - Drug Profile
- CPP-115 - Drug Profile
- D-473 - Drug Profile
- Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
- E-2508 - Drug Profile
- evenamide - Drug Profile
- FKW-00GA - Drug Profile
- fluvoxamine maleate - Drug Profile
- ganaxolone - Drug Profile
- gepirone hydrochloride ER - Drug Profile
- GT-001 - Drug Profile
- HL-9001 - Drug Profile
- HUF-101 - Drug Profile
- IC-87201 - Drug Profile
- INT-0036 - Drug Profile
- INV-107 - Drug Profile
- ITI-007 - Drug Profile
- KDAC-0001 - Drug Profile
- ketamine hydrochloride - Drug Profile
- lorazepam - Drug Profile
- lorazepam ER - Drug Profile
- LSN-2535717 - Drug Profile
- LY-2607540 - Drug Profile
- midazolam hydrochloride - Drug Profile
- modafinil - Drug Profile
- nabiximols - Drug Profile
- NC-2800 - Drug Profile
- NEO-1940 - Drug Profile
- NNI-351 - Drug Profile
- NSI-189 - Drug Profile
- OMS-527 - Drug Profile
- Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile
- PGT-117 - Drug Profile
- PH-94B - Drug Profile
- PN-6047 - Drug Profile
- PT-00114 - Drug Profile
- remeglurant - Drug Profile
- riluzole - Drug Profile
- Rycal - Drug Profile
- S-107 - Drug Profile
- SCT-66 - Drug Profile
- Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
- Small Molecule to Agonize CB1 Receptor for Inflammatory and Neuropathic Pain - Drug Profile
- Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile
- Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile
- Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder - Drug Profile
- Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile
- Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
- Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
- Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile
- Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile
- Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile
- Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile
- Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
- Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile
- Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile
- Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile
- Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile
- Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
- Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
- Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
- Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile
- Small Molecules to Modulate Mineralocorticoid Receptor for Anxiety Disorders and Depression - Drug Profile
- Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile
- Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile
- Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
- SRX-246 - Drug Profile
- SRX-251 - Drug Profile
- STX - Drug Profile
- Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
- TGFK-08AA - Drug Profile
- TGSC-01AA(4) - Drug Profile
- TNX-102 - Drug Profile
- TRV-250 - Drug Profile
- UCM-765 - Drug Profile
- Vaccine for CNS Disorders - Drug Profile
- VAD-1 - Drug Profile
- VAD-2 - Drug Profile
- VU-0431316 - Drug Profile
- VU-0456810 - Drug Profile
- ZL-006 - Drug Profile
- Anxiety Disorders - Dormant Projects
- Anxiety Disorders - Discontinued Products
- Anxiety Disorders - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Anxiety Disorders, H2 2016
- Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Development by Companies, H2 2016 (Contd..1)
- Number of Products under Development by Companies, H2 2016 (Contd..2)
- Number of Products under Development by Companies, H2 2016 (Contd..3)
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Late Stage Development, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Development, H2 2016
- Comparative Analysis by Unknown Stage Development, H2 2016
- Products under Development by Companies, H2 2016
- Products under Development by Companies, H2 2016 (Contd..1)
- Products under Development by Companies, H2 2016 (Contd..2)
- Products under Development by Companies, H2 2016 (Contd..3)
- Products under Development by Companies, H2 2016 (Contd..4)
- Products under Development by Companies, H2 2016 (Contd..5)
- Products under Investigation by Universities/Institutes, H2 2016
- Anxiety Disorders - Pipeline by AbbVie Inc, H2 2016
- Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
- Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2016
- Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2016
- Anxiety Disorders - Pipeline by Amorsa Therapeutics Inc., H2 2016
- Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016
- Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
- Anxiety Disorders - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
- Anxiety Disorders - Pipeline by Bionomics Limited, H2 2016
- Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2016
- Anxiety Disorders - Pipeline by C4X Discovery Holdings PLC, H2 2016
- Anxiety Disorders - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
- Anxiety Disorders - Pipeline by Corcept Therapeutics Incorporated, H2 2016
- Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2016
- Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2016
- Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2016
- Anxiety Disorders - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
- Anxiety Disorders - Pipeline by Gabather AB, H2 2016
- Anxiety Disorders - Pipeline by GlaxoSmithKline Plc, H2 2016
- Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H2 2016
- Anxiety Disorders - Pipeline by Humanetics Corporation, H2 2016
- Anxiety Disorders - Pipeline by IntelGenx Corp., H2 2016
- Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
- Anxiety Disorders - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
- Anxiety Disorders - Pipeline by Lead Discovery Center GmbH, H2 2016
- Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
- Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
- Anxiety Disorders - Pipeline by Neuralstem, Inc., H2 2016
- Anxiety Disorders - Pipeline by Neurelis, Inc., H2 2016
- Anxiety Disorders - Pipeline by NeuroNascent, Inc., H2 2016
- Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
- Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
- Anxiety Disorders - Pipeline by Omeros Corporation, H2 2016
- Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
- Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
- Anxiety Disorders - Pipeline by Pragma Therapeutics, H2 2016
- Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H2 2016
- Anxiety Disorders - Pipeline by Suda Ltd, H2 2016
- Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
- Anxiety Disorders - Pipeline by Synchroneuron Inc., H2 2016
- Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
- Anxiety Disorders - Pipeline by Toray Industries, Inc., H2 2016
- Anxiety Disorders - Pipeline by Trevena, Inc., H2 2016
- Anxiety Disorders - Pipeline by TRImaran Pharma, Inc., H2 2016
- Anxiety Disorders - Pipeline by Turing Pharmaceuticals AG , H2 2016
- Assessment by Monotherapy Products, H2 2016
- Number of Products by Stage and Target, H2 2016
- Number of Products by Stage and Mechanism of Action, H2 2016
- Number of Products by Stage and Route of Administration, H2 2016
- Number of Products by Stage and Molecule Type, H2 2016
- Anxiety Disorders - Dormant Projects, H2 2016
- Anxiety Disorders - Dormant Projects (Contd..1), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..2), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..3), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..4), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..5), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..6), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..7), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..8), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..9), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..10), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..11), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..12), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..13), H2 2016
- Anxiety Disorders - Dormant Projects (Contd..14), H2 2016
- Anxiety Disorders - Discontinued Products, H2 2016
- Anxiety Disorders - Discontinued Products (Contd..1), H2 2016
- Anxiety Disorders - Discontinued Products (Contd..2), H2 2016
- Anxiety Disorders - Discontinued Products (Contd..3), H2 2016
- Anxiety Disorders - Discontinued Products (Contd..4), H2 2016
- List of Figures
- Number of Products under Development for Anxiety Disorders, H2 2016
- Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Number of Products by Top 10 Targets, H2 2016
- Number of Products by Stage and Top 10 Targets, H2 2016
- Number of Products by Top 10 Mechanism of Actions, H2 2016
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
- Number of Products by Routes of Administration, H2 2016
- Number of Products by Stage and Routes of Administration, H2 2016
- Number of Products by Molecule Types, H2 2016
- Number of Products by Stage and Molecule Types, H2 2016
Description
Anxiety Disorders - Pipeline Review, H2 2016 Description
Global Markets Direct
Anxiety Disorders - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Anxiety Disorders - Pipeline Review, H2 2016’, provides an overview of the Anxiety Disorders pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
Scope
- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Search inside this report
| Single User License | $2,000 | |
|---|---|---|
| Site License | $4,000 | |
| Global Site License | $6,000 |
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
